AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03028103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
Study NCT03028103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
Study NCT03177057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Record behavior
Study NCT03177057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Receive health monitoring text messages
Study NCT03177057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03453567 — intervention group
Intervention type: PROCEDURE
Intervention: Valve Replacement
Description: Aortic valve replacement
Study NCT04116489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forest walk
Description: Participants will be provided with an educational program about the forest and take a guided forest walk.
Study NCT04116489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wildlife rehabilitation
Description: Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
Study NCT04116489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wildlife sanctuary observation
Description: Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
Study NCT04116489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bird feeding and watching
Description: Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
Study NCT01107496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IR Viloxazine
Description: One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6.
Study NCT01107496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally 3 times a day
Study NCT02473562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for varenicline)
Description: Tablet 1 mg BID
Study NCT01555580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Description: Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
Study NCT01715870 — intervention group
Intervention type: BEHAVIORAL
Intervention: Life style and food habits questionnaire
Study NCT04666740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
Study NCT04666740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
Study NCT04361487 — intervention group
Intervention type: DEVICE
Intervention: NOVOSTITCH PRO Meniscal Repair System
Description: Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
Study NCT01587196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: There are monthly injections of depot naltrexone for 3 months.
Study NCT01355627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
Study NCT01355627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Practice
Description: Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®.
Study NCT04305756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Low molecular weight heparin
Study NCT04305756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Low molecular weight heparin
Study NCT03161262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based reminders
Description: The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
Study NCT05721079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECP (Extracorporeal Photopheresis System)
Description: Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
Study NCT05721079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECP (Extracorporeal Photopheresis System)
Description: Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
Study NCT01092650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated phenanthrene
Description: Deuterated phenanthrene 10 micrograms
Study NCT03177057 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04275570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview
Description: The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
Study NCT01092650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deuterated phenanthrene
Description: Deuterated phenanthrene 10 micrograms
Study NCT01356147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase alfa
Description: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Study NCT01852305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab Sleep Study Group
Description: Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
Study NCT01852305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oximetry
Description: The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
Study NCT02544178 — intervention group
Intervention type: RADIATION
Intervention: brain radiotherapy
Description: effect of cerebral radiotherapy on neurocognitive state
Study NCT03458975 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: Magnetic Resonance Imaging
Study NCT03458975 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Magnetic Resonance Imaging
Study NCT03458975 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Perfusion CT scan
Description: Perfusion Computerized tomography scan
Study NCT02166801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
Study NCT03635697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Auditory Intervention
Description: This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
Study NCT03695211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional landmark technique
Description: inject at the midpoint of the posterior border of the sternocleidomastoid muscle
Study NCT03695211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precise block technique
Description: inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
Study NCT01623804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low intensity, pulsed ultrasound
Description: 1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
Study NCT01623804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
Study NCT03285919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Assessment Robot (BAR™)
Description: The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered.
Study NCT03285919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Assessment Robot (BAR™)
Description: The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered.
Study NCT01356147 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No therapy will be given to placebo arm
Study NCT02245659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure
Study NCT02245659 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal dilator strip
Description: Nasal dilator strip to be worn nightly
Study NCT00974272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 μg)
Study NCT00974272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single subcutaneous injection
Study NCT03458975 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion CT scan
Description: Perfusion Computerized tomography scan
Study NCT03458975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Contrast enhanced ultrasound
Study NCT03458975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Contrast enhanced ultrasound
Study NCT03458975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonoporation
Description: Gaseous microbubbles (Sonovue) combinated with Ultrasounds
Study NCT04894695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers detection in different groups
Description: Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
Study NCT03890562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
Study NCT04167696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYAD-02
Description: CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
Study NCT04167696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENDOXAN
Description: administered as preconditioning chemotherapy
Study NCT04167696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: administered as preconditioning chemotherapy
Study NCT01122316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
Study NCT02466334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin-Gene Related Peptide
Description: 1,5 µg/min of IV CGRP over 20 mins
Study NCT02466334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 ml of normal saline over 20 mins
Study NCT02821949 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCT dosage
Description: When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
Study NCT04973813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + Active Choice + action&coping planning (GA+)
Description: Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
Study NCT04973813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + Active Choice (GA)
Description: Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
Study NCT04973813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + information (GI)
Description: Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
Study NCT04973813 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Guideline (G)
Description: Web-based information about the national physical activity guideline.
Study NCT02588820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (Experimental)
Description: 1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day
Study NCT04512950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
Study NCT04512950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
Study NCT04726670 — intervention group
Intervention type: OTHER
Intervention: Evaluation of postoperative pain
Description: A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit.
Study NCT01601132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline
Description: 300mg (80mg/15ml elixir)
Study NCT01601132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
Study NCT04578483 — intervention group
Intervention type: OTHER
Intervention: PCA group
Description: Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
Study NCT04578483 — intervention group
Intervention type: OTHER
Intervention: ERDS group
Description: After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
Study NCT00384657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure.
Study NCT01782547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;